In addition, the study examined lipid levels in mice fed the high fat diet and either treated with XOMA 052 or the control. Without treatment, mice eating the high fat diet showed increases in the blood levels of lipids like total cholesterol, triglycerides and free fatty acids. The mice treated with XOMA 052 demonstrated reduced levels of lipids compared to the control.

XOMA also announced that two posters on XOMA 052 in the treatment of Type 2 diabetes will be presented at the American Diabetes Association 70th Scientific Sessions, occurring June 25 through June 29, 2010. A third abstract from XOMA was accepted on a published-only basis. The two posters will be presented on June 28 between 12 noon and 2:00 PM Eastern time. They are entitled:

Combination Studies of the Anti-Interleukin-1beta Monoclonal Antibody XOMA 052 with Exendin-4 or Sitagliptin in a Diet-Induced Obesity Mouse Model of Type 2 Diabetes Mellitus Inhibition of Interleukin-1beta with the Monoclonal Antibody XOMA 052 Reveals the Differential Sensitivities of Glycemic and Pancreatic Function Parameters to Chronic Inflammation

The published-only abstract is entitled:

The Role of Interleukin-1beta in Insulin Resistance SOURCE XOMA Ltd.